Biocon gets US FDA approval for fifth cancer biosimilar Pebrilzo
Biocon has received US Food and Drug Administration approval for Pebrilzo (pertuzumab-qcay), a biosimilar to Genentech's Perjeta used in HER2-positive breast cancer. It is the company's fifth oncology biosimilar to clear the…







































Ashin Xavier: interesting
IO Repro: Repro test v4 after fix 2 Oct. Safe to trash.
IO Repro: Repro test v3 after fix 2 Oct. Safe to trash.
IO Repro: Repro test after fix 2 Oct. Safe to trash.